Cyclacel Pharmaceuticals (CYCC +17.3%) pops today after announcing earlier that it will present...
Tuesday, December 4, 2012, 1:44 PM ETCyclacel Pharmaceuticals (CYCC +17.3%) pops today after announcing earlier that it will present analysis of Phase III testing of its leukemia drug candidates Sapacitabine and Decitabine. The testing was administered in alternating cycles in elderly patients with newly diagnosed acute myeloid leukemia at American Society of Hemoatology convention in Atlanta this weekend.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles